Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tegaserod · 11 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| Tegaserod | DRUG | - |
Inclusion Criteria: * Male or female subjects at least 18 years of age. * Subjects willing to undergo multiple nasogastric intubations. * Patients with functional heartburn will need to meet ROME II criteria. * Patients with symptoms consistent with dyspepsia (epigastric pain/discomfort characteriz...
Tegaserod is a small molecule drug developed by Novartis AG (ticker NVS) for gastrointestinal conditions. It has been studied in chronic constipation, constipation, dyspepsia, gastroesophageal reflux disease (GERD), heartburn, and symptomatic gastroesophageal reflux disease. It is a partial agonist of the HTR4 receptor and has been evaluated in Phase 3 clinical trials.
Tegaserod has been studied for chronic constipation, constipation, dyspepsia, gastroesophageal reflux disease (GERD), heartburn, and symptomatic gastroesophageal reflux disease. Its clinical trial program focused on dyspepsia in women. It is an investigational small molecule developed by Novartis AG for gastrointestinal disorders.
Tegaserod targets HTR4, also known as the serotonin 5-HT4 receptor, where it acts as a partial agonist. This receptor activity is the basis for its investigation in gastrointestinal motility and functional bowel disorders such as chronic constipation and dyspepsia.
Tegaserod is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 3 clinical trial program evaluating Tegaserod in women with dyspepsia and other gastrointestinal conditions.
Tegaserod is in Phase 3 clinical development. Five Phase 3 trials have been completed, with no active trials currently listed. The studies enrolled a total of 3,434 participants and evaluated Tegaserod in gastrointestinal conditions including dyspepsia, chronic constipation, and GERD.
Tegaserod has been evaluated in completed Phase 3 trials including NCT00232102, NCT00232089, NCT00232037, and NCT00232024. These studies assessed the efficacy and safety of Tegaserod versus placebo and long-term safety in women with dyspepsia, with enrollment ranging from 359 to 1,296 participants per trial.